Corrigendum: Chloroquine Inhibits Stemness of Esophageal Squamous Cell Carcinoma Cells Through Targeting CXCR4-STAT3 Pathway
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Frontiers in Oncology - 12(2022) |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dongli Yue [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
CXCR4 |
|---|
| doi: |
10.3389/fonc.2022.860158 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ014318369 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ014318369 | ||
| 003 | DE-627 | ||
| 005 | 20230502120036.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fonc.2022.860158 |2 doi | |
| 035 | |a (DE-627)DOAJ014318369 | ||
| 035 | |a (DE-599)DOAJ202c58e8772d4e9f89d9808b2fa61656 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC254-282 | |
| 100 | 0 | |a Dongli Yue |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Corrigendum: Chloroquine Inhibits Stemness of Esophageal Squamous Cell Carcinoma Cells Through Targeting CXCR4-STAT3 Pathway |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 650 | 4 | |a esophageal squamous cell carcinoma (ESCC) | |
| 650 | 4 | |a cancer stem cells (CSCs) | |
| 650 | 4 | |a CXCR4 | |
| 650 | 4 | |a chloroquine (CQ) | |
| 650 | 4 | |a STAT3 | |
| 653 | 0 | |a Neoplasms. Tumors. Oncology. Including cancer and carcinogens | |
| 700 | 0 | |a Dongli Yue |e verfasserin |4 aut | |
| 700 | 0 | |a Daiqun Zhang |e verfasserin |4 aut | |
| 700 | 0 | |a Xiaojuan Shi |e verfasserin |4 aut | |
| 700 | 0 | |a Shasha Liu |e verfasserin |4 aut | |
| 700 | 0 | |a Anqi Li |e verfasserin |4 aut | |
| 700 | 0 | |a Dong Wang |e verfasserin |4 aut | |
| 700 | 0 | |a Dong Wang |e verfasserin |4 aut | |
| 700 | 0 | |a Guohui Qin |e verfasserin |4 aut | |
| 700 | 0 | |a Guohui Qin |e verfasserin |4 aut | |
| 700 | 0 | |a Yu Ping |e verfasserin |4 aut | |
| 700 | 0 | |a Yamin Qiao |e verfasserin |4 aut | |
| 700 | 0 | |a Yamin Qiao |e verfasserin |4 aut | |
| 700 | 0 | |a Xinfeng Chen |e verfasserin |4 aut | |
| 700 | 0 | |a Xinfeng Chen |e verfasserin |4 aut | |
| 700 | 0 | |a Feng Wang |e verfasserin |4 aut | |
| 700 | 0 | |a Renyin Chen |e verfasserin |4 aut | |
| 700 | 0 | |a Song Zhao |e verfasserin |4 aut | |
| 700 | 0 | |a Lidong Wang |e verfasserin |4 aut | |
| 700 | 0 | |a Yi Zhang |e verfasserin |4 aut | |
| 700 | 0 | |a Yi Zhang |e verfasserin |4 aut | |
| 700 | 0 | |a Yi Zhang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Frontiers in Oncology |d Frontiers Media S.A., 2012 |g 12(2022) |w (DE-627)DOAJ000099678 |x 2234943X |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2022 |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fonc.2022.860158 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/202c58e8772d4e9f89d9808b2fa61656 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.frontiersin.org/articles/10.3389/fonc.2022.860158/full |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2234-943X |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2022 | ||